Regeneron's Less Frequent Eylea Dosing Makes Late Sprint Across FDA Finish Line
Executive Summary
Regeneron's blockbuster AMD biologic Eylea improved its ability to compete with future longer-acting VEGF inhibitors with a label supporting every dosing every 12 weeks; the company's less frequent regimen cleared FDA five days after receiving a complete response letter.
You may also be interested in...
Interview: Novartis's Big Hopes For Beovu
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.
Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Label Battles: Beovu And Eylea Contest Begins In AMD
Shares in Eylea-maker Regeneron slid after FDA approved Novartis's competing VEGF inhibitor for treating AMD, but some observers said investors had overreacted.